

Ehab Atallah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7142608/publications.pdf>

Version: 2024-02-01

72
papers

1,331
citations

394421

19
h-index

395702

33
g-index

73
all docs

73
docs citations

73
times ranked

1763
citing authors

#	ARTICLE	IF	CITATIONS
1	Congestive heart failure is a rare event in patients receiving imatinib therapy. <i>Blood</i> , 2007, 110, 1233-1237.	1.4	233
2	Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 214-221.e1.	0.4	63
3	Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia Research</i> , 2018, 73, 21-23.	0.8	62
4	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019, 3, 508-518.	5.2	62
5	A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 139-145.	0.4	60
6	Follow-up of patients with R/R FLT3-mutation positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	1.4	55
7	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42.	7.1	51
8	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. <i>OncoTargets and Therapy</i> , 2013, 7, 13.	2.0	46
9	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. <i>JAMA Oncology</i> , 2020, 6, 486.	7.1	39
10	Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 80-85.	2.3	37
11	Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 449-457.	5.2	37
12	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	5.2	29
13	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 663-670.	2.4	28
14	Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?. <i>Haematologica</i> , 2020, 105, 2738-2745.	3.5	28
15	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. <i>Leukemia Research</i> , 2020, 95, 106385.	0.8	26
16	Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. <i>Leukemia and Lymphoma</i> , 2019, 60, 1171-1178.	1.3	25
17	Incidence and survival of therapy related myeloid neoplasm in United States. <i>Leukemia Research</i> , 2018, 71, 95-99.	0.8	24
18	Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	24

#	ARTICLE	IF	CITATIONS
19	Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e1-e5.	0.4	22
20	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 453-453.	1.4	20
21	Dasatinib dose management for the treatment of chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 1660-1672.	4.1	19
22	A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. <i>Blood</i> , 2014, 124, LBA-5-LBA-5.	1.4	19
23	A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. <i>Blood</i> , 2016, 128, 100-100.	1.4	18
24	Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. <i>Blood</i> , 2015, 126, 908-908.	1.4	17
25	Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 1253-1258.	3.7	16
26	Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	4.1	16
27	Treatment-Free Remission: the New Goal in CML Therapy. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 433-439.	2.3	16
28	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018, 18, 359.	2.6	15
29	Treatment Strategies in Myelodysplastic Syndromes. <i>Cancer Investigation</i> , 2008, 26, 208-216.	1.3	13
30	Treatment-Free Remission in CML: the US Perspective. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 56-61.	2.3	13
31	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.4	12
32	Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study. <i>Blood</i> , 2009, 114, 2089-2089.	1.4	12
33	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). <i>Blood</i> , 2014, 124, 163-163.	1.4	12
34	Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 57-65.	2.3	11
35	Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 480-487.	0.4	11
36	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	2.4	11

#	ARTICLE	IF	CITATIONS
37	Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I. <i>Blood</i> , 2012, 120, 1733-1733.	1.4	11
38	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. <i>Blood</i> , 2015, 126, 193-193.	1.4	11
39	Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 468-479.	3.8	10
40	Incorporating newer agents in the treatment of acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 74, 113-120.	0.8	9
41	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 160-164.	6.3	9
42	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
43	Chronic Myeloid Leukemia—the Promise of Tyrosine Kinase Inhibitor Discontinuation. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 415-423.	2.3	7
44	Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. <i>Case Reports in Hematology</i> , 2018, 2018, 1-6.	0.4	6
45	Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Blood</i> , 2008, 112, 3651-3651.	1.4	6
46	Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. <i>American Journal of Hematology</i> , 2010, 85, 579-583.	4.1	5
47	Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. <i>American Journal of Hematology</i> , 2017, 92, E563-E565.	4.1	4
48	Patients'™ perspectives on the definition of cure in chronic myeloid leukemia. <i>Leukemia Research</i> , 2019, 80, 40-42.	0.8	4
49	Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. <i>Haematologica</i> , 2022, 107, 2641-2649.	3.5	4
50	A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. <i>Journal of Cancer Prevention</i> , 2022, 27, 129-138.	2.0	4
51	Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 2081-2081.	1.4	3
52	The Outcome of Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in Adults ≥65 Years of Age: First Report of the Coverage with Evidence Development (CED) in Medicare Beneficiaries. <i>Blood</i> , 2012, 120, 1983-1983.	1.4	3
53	Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes. <i>Blood</i> , 2014, 124, 1851-1851.	1.4	3
54	Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S101-S102.	2.0	2

#	ARTICLE	IF	CITATIONS
55	Do histone deacetylase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?. Expert Opinion on Investigational Drugs, 2021, 30, 665-673.	4.1	2
56	Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2014, 124, 947-947.	1.4	2
57	Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals. Blood, 2016, 128, 2784-2784.	1.4	2
58	Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginaseâ€”A real world study. Leukemia Research, 2020, 94, 106368.	0.8	2
59	Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future?. Expert Opinion on Pharmacotherapy, 2018, 19, 79-81.	1.8	1
60	Comparison of Outcomes After Related and Unrelated Hematopoietic Cell Transplantation in Adults with Myelodysplastic Syndromes: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 2012, 120, 355-355.	1.4	1
61	Incidence and Overall Survival of Therapy Related Myeloid Neoplasm in United States. Blood, 2016, 128, 3992-3992.	1.4	1
62	Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges. JCO Oncology Practice, 2022, , OP2200237.	2.9	1
63	In Reply. Oncologist, 2020, 25, e744-e745.	3.7	0
64	Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality.. Blood, 2009, 114, 4157-4157.	1.4	0
65	The Effect of Hyperglycemia On the Outcome of Patients with Acute Myelogenous Leukemia. Blood, 2012, 120, 4323-4323.	1.4	0
66	Poor Response To Imatinib In Patients With Secondary Chronic Myelogenous Leukemia. Blood, 2013, 122, 5170-5170.	1.4	0
67	Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). Blood, 2014, 124, 3259-3259.	1.4	0
68	A Statistical Model for Predicting Neutropenic Fever. Blood, 2014, 124, 5258-5258.	1.4	0
69	D-Dimer Kinetics, Chemotherapy and Risk of Bleeding in Acute Promyelocytic Leukemia. Blood, 2014, 124, 1490-1490.	1.4	0
70	Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML). Blood, 2015, 126, 4954-4954.	1.4	0
71	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. Blood, 2015, 126, 2711-2711.	1.4	0
72	Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL). Blood, 2016, 128, 5192-5192.	1.4	0